Key facts
- RedShiftBio’s last known valuation is $87.9M (Jun 2025).
- It has raised $101.3M; the latest was Later Stage VC ($5.9M) in Jun 2025.
- Notable investors include Illumina Ventures, Hercules Capital (San Mateo), Joe Romamo, Technology Venture Partners (US), Waters.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for RedShiftBio
- ·The full record, as it builds
Funding rounds
No funding rounds for RedShiftBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RedShiftBio
Developer of bio-analytical instrumentation designed to transform protein characterization. The company's tools combine laser, microfluidics and analytical technologies for the development of protein therapeutic drugs, as well as the measurement of protein-based drug therapies, enabling scientists to detect and monitor protein conformation and conduct label-free protein analysis.
- Sector
- Healthcare
- HQ
- Boxborough, MA, United States
- Founded
- 2005
- Employees
- 29
- Website
- redshiftbio.com/
- Ownership
- Privately Held (backing)
RedShiftBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RedShiftBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RedShiftBio in its N-PORT filings yet. We sweep new filings monthly.